Wikidata |

Wikidata

Matches in Wikidata for { <http://www.wikidata.org/entity/Q93096897> ?p ?o ?g. }

Showing items 1 to 100 of ±133 with 100 items per page.

Q93096897 description "artículu científicu espublizáu n'abril de 2019" @default.
Q93096897 description "scientific article published on 15 April 2019" @default.
Q93096897 description "wetenschappelijk artikel" @default.
Q93096897 description "наукова стаття, опублікована 15 квітня 2019" @default.
Q93096897 name "Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl" @default.
Q93096897 name "Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl" @default.
Q93096897 type Item @default.
Q93096897 label "Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl" @default.
Q93096897 label "Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl" @default.
Q93096897 prefLabel "Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl" @default.
Q93096897 prefLabel "Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl" @default.
Q93096897 P1104 Q93096897-168B6EC1-434C-4467-B91D-92427FF48A4F @default.
Q93096897 P1433 Q93096897-B0B10449-C86B-42A3-853A-C4D7F570F41C @default.
Q93096897 P1476 Q93096897-CA837806-0479-4D0C-9FB5-6C1334D6B8BD @default.
Q93096897 P2093 Q93096897-32A3BE37-84F5-4B92-BD29-35246AFD99D4 @default.
Q93096897 P2093 Q93096897-844277FA-DB70-4BA8-B5C1-A683D7FF07D2 @default.
Q93096897 P2093 Q93096897-D72C1562-F641-4E81-A42C-29A9A5550AA8 @default.
Q93096897 P2860 Q93096897-01233944-70FD-421E-BCCA-EE98721278EB @default.
Q93096897 P2860 Q93096897-028886E3-9298-4644-93FA-53D955DAACF1 @default.
Q93096897 P2860 Q93096897-036EE9B1-0629-4C19-9EA2-384F61DEA82A @default.
Q93096897 P2860 Q93096897-061682C7-643E-4C30-8E43-2F4E02500266 @default.
Q93096897 P2860 Q93096897-07FF4396-3D66-45F0-BC62-A697B36AEEE1 @default.
Q93096897 P2860 Q93096897-0CAB5D8F-910C-40DF-9EA5-9B367577801F @default.
Q93096897 P2860 Q93096897-13689F66-D343-4357-9C8E-38C703CD1B52 @default.
Q93096897 P2860 Q93096897-170927C5-1F59-4E31-BF1C-47D2E768B40E @default.
Q93096897 P2860 Q93096897-1A3864F6-3C00-48DC-86D9-5409A0AF9080 @default.
Q93096897 P2860 Q93096897-1E650EDB-1BA3-4B2D-A499-453C45C2BC0C @default.
Q93096897 P2860 Q93096897-275A89A0-A749-4E6D-B44F-77730525B836 @default.
Q93096897 P2860 Q93096897-27B719CD-575D-45BA-B635-7BA0787C4F54 @default.
Q93096897 P2860 Q93096897-291FE258-DD26-4550-9DE9-B78D6E527E99 @default.
Q93096897 P2860 Q93096897-31CD16E0-23B1-4B51-91FA-6B252BD22F7C @default.
Q93096897 P2860 Q93096897-41E34D92-AE55-4051-80FB-329229277D33 @default.
Q93096897 P2860 Q93096897-59655E6B-36D8-49F9-8B73-EA1961455640 @default.
Q93096897 P2860 Q93096897-6DB314D8-9635-46F6-9D5D-B06CFA99FA7A @default.
Q93096897 P2860 Q93096897-6ED1AFA5-0DFC-4B83-B92C-B7E0EA513C44 @default.
Q93096897 P2860 Q93096897-70461A32-F6CC-4D52-B530-580DCCB4394B @default.
Q93096897 P2860 Q93096897-7637DB12-66EE-44C3-BBAC-421D4A99D6D6 @default.
Q93096897 P2860 Q93096897-7BACAF31-8C8D-40DA-A8C9-58F90F26B28E @default.
Q93096897 P2860 Q93096897-85085896-4CE4-4697-A132-1F0BBE9ECD95 @default.
Q93096897 P2860 Q93096897-8AC3C62F-C18A-4F79-8D0B-AB3A4173ED8B @default.
Q93096897 P2860 Q93096897-9153AB0F-23BF-4BCA-AF61-BDACFF0B907E @default.
Q93096897 P2860 Q93096897-98B26674-172B-4947-8D38-897719B60E7A @default.
Q93096897 P2860 Q93096897-AE434CE2-62F0-4122-90DA-BCE261E8696E @default.
Q93096897 P2860 Q93096897-C000782F-DFAE-4D81-962D-7B782F2F962E @default.
Q93096897 P2860 Q93096897-D3371AD2-90CB-4D48-B6CC-D749E6FF4FA1 @default.
Q93096897 P304 Q93096897-2C317DFB-7110-407B-9F48-496D5FEEBB1B @default.
Q93096897 P31 Q93096897-DBF02FA7-FAF1-4749-924E-92D535F68E34 @default.
Q93096897 P356 Q93096897-019476A7-0B1E-4CF7-9100-2DD65F6EB8DB @default.
Q93096897 P433 Q93096897-C9355C21-4915-4E64-9172-8D59B8E032D7 @default.
Q93096897 P478 Q93096897-C8FF108E-0784-4F7F-A405-F3A628AEF6E6 @default.
Q93096897 P50 Q93096897-0786D8EF-A703-4FA8-B492-249FFC0E796B @default.
Q93096897 P50 Q93096897-0CFC151D-928D-470D-B2E7-3AFAD83AA2FF @default.
Q93096897 P50 Q93096897-0DCB0A9A-A12C-4F39-9DAC-13C583EF22A0 @default.
Q93096897 P50 Q93096897-1BEF9233-987B-4925-B5ED-D9F9BA0FFA16 @default.
Q93096897 P50 Q93096897-4A409071-EC4D-438B-8C18-062A6D917991 @default.
Q93096897 P50 Q93096897-60F925FF-C876-4F7D-BF96-28FD9CA2DB27 @default.
Q93096897 P50 Q93096897-71C2CE5F-0E1F-468E-B784-2D1E24406278 @default.
Q93096897 P50 Q93096897-7F73BF47-81F4-4F5F-9A7A-47A907E731EB @default.
Q93096897 P50 Q93096897-8F19A90B-61F7-4290-BA24-6FAC0130E162 @default.
Q93096897 P50 Q93096897-9001F1E9-ECDE-4B1C-B24D-138BFC5B8420 @default.
Q93096897 P50 Q93096897-BEFAAAD0-5895-4C73-AE27-A4418D37C489 @default.
Q93096897 P50 Q93096897-C08B1050-1992-42EC-8CA9-C6842BEF2280 @default.
Q93096897 P50 Q93096897-C3239603-E161-44EE-B1AF-25948AB8DF08 @default.
Q93096897 P50 Q93096897-CBE01D01-C14D-4206-ADC1-D7B1F35C5BA0 @default.
Q93096897 P50 Q93096897-D7AD90AC-B8D2-4B01-A302-95C9A1B9149D @default.
Q93096897 P50 Q93096897-F6C51725-5A87-438F-BF50-EFBA36FE5109 @default.
Q93096897 P577 Q93096897-1E7E6F60-258A-4956-AC94-D2CC2EA93A54 @default.
Q93096897 P698 Q93096897-65EE2ABC-B0A5-4928-B36A-10DC43F9787D @default.
Q93096897 P921 Q93096897-E0C6F5EE-07B4-43E3-877D-FA40C4D7EA28 @default.
Q93096897 P921 Q93096897-FC1C7BBA-F3D1-4B03-A7E7-3F554FB0F6B9 @default.
Q93096897 P932 Q93096897-1AAE253B-4C2A-41CD-9A60-9A56EC23DFB4 @default.
Q93096897 P356 CNCR.32139 @default.
Q93096897 P698 30985931 @default.
Q93096897 P1104 "+8" @default.
Q93096897 P1433 Q326041 @default.
Q93096897 P1476 "Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis" @default.
Q93096897 P2093 "Farhad Ravandi" @default.
Q93096897 P2093 "Nitin Jain" @default.
Q93096897 P2093 "Philip Thompson" @default.
Q93096897 P2860 Q33843477 @default.
Q93096897 P2860 Q34131844 @default.
Q93096897 P2860 Q34350665 @default.
Q93096897 P2860 Q34565132 @default.
Q93096897 P2860 Q34737471 @default.
Q93096897 P2860 Q36751420 @default.
Q93096897 P2860 Q36781942 @default.
Q93096897 P2860 Q37564762 @default.
Q93096897 P2860 Q38428357 @default.
Q93096897 P2860 Q38688978 @default.
Q93096897 P2860 Q39419031 @default.
Q93096897 P2860 Q39796888 @default.
Q93096897 P2860 Q39849626 @default.
Q93096897 P2860 Q40295439 @default.
Q93096897 P2860 Q40312849 @default.
Q93096897 P2860 Q40591760 @default.
Q93096897 P2860 Q40705613 @default.
Q93096897 P2860 Q41962966 @default.
Q93096897 P2860 Q46317683 @default.
Q93096897 P2860 Q48311791 @default.
Q93096897 P2860 Q49905062 @default.